Eleven prepubertal children with short stature were treated with clonidine (0.15 mg/m2 daily) for a period of 1 year. The effect of this drug was evaluated on both clinical (growth velocity, height standard deviation scores for chronological age and bone age) and hormonal (urinary growth hormone excretion and insulin-like growth factor I) parameters. Our study shows that long-term clonidine administration in children with short stature did not result in significant differences in growth velocity, height standard deviation scores for chronological age and bone age, insulin-like growth factor I or in urinary growth hormone excretion.

Growth velocity

10.1159/000181824

Cite

Citations (3)

Growth hormone secretion assessment in the diagnosis of short stature.

PubMed (1996)

Laura Audı́M.L. Granada Antonio Carrascosa

Growth hormone (GH) secretion assessment in the diagnosis of short stature presents certain problems in relation to the protocols designed for it and the interpretation of results. GH measurement in serum may be accompanied by IGF-I and IGFBP-3 measurements, and in some patients by GHBP measurement. Protocols for evaluating GH response to acute stimuli or spontaneous secretion are tedious, sometimes hazardous and difficult to interpret. This is due to the wide variation in responses observed in normally-growing children, to the age-dependent changes in these parameters and, in the case of GH, to the wide variation in immunoassay results. New techniques able to measure biologically-active GH molecules circulating in blood may help to simplify diagnosis. Severe idiopathic or organic GH deficiency poses no diagnostic problems. GH secretory insufficiency may be diagnosed as partial, idiopathic, isolated GH deficiency or as neurosecretory dysfunction. Clear cut-off values for these diagnoses and the possibility of a transient reversible pathology are not well established. Analysis of large series of children with different diagnoses in whom the growth pattern, either spontaneous or under rhGH treatment, final height and GH secretion re-evaluation at the end of growth were studied will help to clarify GH secretion or action abnormalities in these patients.

Idiopathic short stature

Source

Cite

Citations (15)

Does oral paricalcitol have an antiproteinuric and bone formation effect in renal transplant patients

F1000Research (2011)

Ana Sánchez-Escuredo Susana Holgado Carmen Biosca M.L. Granada Eva Barluenga

Paricalcitol

Open peer review

10.7490/f1000research.1902.1

Cite

Citations (0)

Announcements

Hormone Research (1990)

A. Sanmarti A. Lucas M.L. Granada I. Salinas Jordi L. Reverter

10.1159/000181837

Cite

Citations (0)

Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population

European Journal of Endocrinology (2000)

M.L. Granada Jorge Murillo Anna Lucas I. Salinas María Antonia Llopis

To analyse the diagnostic role of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH (uGH) excretion in adult GH deficiency (GHD).Twenty-seven adults (age range: 18-71 years) with severe GHD, defined by a peak GH response to an insulin tolerance test below 3microg/l in patients with at least one additional pituitary hypofunction. Reference values were established from a selected age- and body mass index-matched population (154 healthy adults grouped in four age groups).IGF-I and IGFBP-3 were measured by RIA (Nichols) and results expressed as standard deviation (s.d.) scores from our reference population and assay normative data (s.d. score Nichols). uGH was measured by IRMA.Within the control group, IGF-I, IGFBP-3, IGF-I/IGFBP-3 ratio standardisation regarding our control population and IGF-I with respect to the assay normative data resulted in disappearance of age-related differences. However, IGFBP-3 s.d. score Nichols resulted in mean values between +1.4 and +2.5 s.d. score. Greatest diagnostic efficiency was for IGF-I standardised with respect to our controls (97.2%), followed by s.d. score IGFBP-3 (92.9%). s.d. score IGF/IGFBP-3 ratio and uGH showed poor diagnostic efficiency. Any combination of at least two abnormal parameters raised specificity to 100%. IGF-I standardised with respect to assay reference (s.d. score Nichols) showed similar diagnostic value (95.0%) whereas IGFBP-3 showed low sensitivity (33. 3%). Within the GHD patients, those with three or more additional deficiencies had lower s.d. score IGF-I than those with only two or one.We underline the importance of an appropriate reference population for correct interpretation of GH secretion markers. Considering our results, specificity obtained with two simultaneous abnormal parameters when referred to an adequate reference population may add valuable information to alternative GH stimulation tests to confirm adult GHD.

10.1530/eje.0.1420243

Cite

Citations (52)